Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

790 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer.
Lee CK, Simes RJ, Brown C, Lord S, Wagner U, Plante M, Vergote I, Pisano C, Parma G, Burges A, Bourgeois H, Högberg T, Bentley J, Angleitner-Boubenizek L, Ferrero A, Richter B, Hirte H, Gebski V, Pfisterer J, Pujade-Lauraine E, Friedlander M. Lee CK, et al. Among authors: ferrero a. Br J Cancer. 2011 Oct 11;105(8):1144-50. doi: 10.1038/bjc.2011.364. Epub 2011 Sep 13. Br J Cancer. 2011. PMID: 21915127 Free PMC article.
CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial.
Alexandre J, Brown C, Coeffic D, Raban N, Pfisterer J, Mäenpää J, Chalchal H, Fitzharris B, Volgger B, Vergote I, Pisano C, Ferrero A, Pujade-Lauraine E. Alexandre J, et al. Among authors: ferrero a. Br J Cancer. 2012 Feb 14;106(4):633-7. doi: 10.1038/bjc.2011.593. Epub 2012 Jan 12. Br J Cancer. 2012. PMID: 22240800 Free PMC article. Clinical Trial.
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
Gladieff L, Ferrero A, De Rauglaudre G, Brown C, Vasey P, Reinthaller A, Pujade-Lauraine E, Reed N, Lorusso D, Siena S, Helland H, Elit L, Mahner S. Gladieff L, et al. Among authors: ferrero a. Ann Oncol. 2012 May;23(5):1185-1189. doi: 10.1093/annonc/mdr441. Epub 2011 Oct 5. Ann Oncol. 2012. PMID: 21976386 Free article. Clinical Trial.
Significance of serum CA125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up.
van Dalen A, Favier J, Hallensleben E, Burges A, Stieber P, de Bruijn HW, Fink D, Ferrero A, McGing P, Harlozinska A, Kainz Ch, Markowska J, Molina R, Sturgeon C, Bowman A, Einarsson R, Goike H. van Dalen A, et al. Among authors: ferrero a. Eur J Gynaecol Oncol. 2009;30(6):609-15. Eur J Gynaecol Oncol. 2009. PMID: 20099488
The systemic treatment of recurrent ovarian cancer revisited.
Baert T, Ferrero A, Sehouli J, O'Donnell DM, González-Martín A, Joly F, van der Velden J, Blecharz P, Tan DSP, Querleu D, Colombo N, du Bois A, Ledermann JA. Baert T, et al. Among authors: ferrero a. Ann Oncol. 2021 Jun;32(6):710-725. doi: 10.1016/j.annonc.2021.02.015. Epub 2021 Mar 3. Ann Oncol. 2021. PMID: 33675937 Free article. Review.
Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93.
Thürlimann B, Price KN, Gelber RD, Holmberg SB, Crivellari D, Colleoni M, Collins J, Forbes JF, Castiglione-Gertsch M, Coates AS, Goldhirsch A; International Breast Cancer Study Group. Thürlimann B, et al. Breast Cancer Res Treat. 2009 Jan;113(1):137-44. doi: 10.1007/s10549-008-9912-9. Epub 2008 Feb 8. Breast Cancer Res Treat. 2009. PMID: 18259856 Free PMC article. Clinical Trial.
Palliative care in patients with ovarian cancer and bowel obstruction.
Daniele A, Ferrero A, Fuso L, Mineccia M, Porcellana V, Vassallo D, Biglia N, Menato G. Daniele A, et al. Among authors: ferrero a. Support Care Cancer. 2015 Nov;23(11):3157-63. doi: 10.1007/s00520-015-2694-9. Epub 2015 Mar 25. Support Care Cancer. 2015. PMID: 25805450 Free article.
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, D'Amico R, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Gribaudo S, Provencher D, Hanzen C, Kruitwagen RF, Smit VTHBM, Singh N, Do V, Lissoni A, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC Study Group. de Boer SM, et al. Lancet Oncol. 2019 Sep;20(9):1273-1285. doi: 10.1016/S1470-2045(19)30395-X. Epub 2019 Jul 22. Lancet Oncol. 2019. PMID: 31345626 Free PMC article. Clinical Trial.
790 results